Diabetes mellitus and prognosis in women with breast cancer

Zhao, Xiaobo; Ren, Guosheng

doi:10.1097/md.0000000000005602

Cited by 87 publications

(82 citation statements)

References 38 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study based on SEER-Medicare data, women diagnosed with diabetes prior to breast cancer diagnosis had a higher all-cause mortality compared with women without diabetes 20 . In a meta-analysis of seventeen studies, pre-existing diabetics were shown to have a 50% higher all-cause mortality than those without diabetes 21 . To the best of our knowledge, the association between diabetes diagnosed at or after breast cancer diagnosis and survival has not been studied.…”

Section: Introductionmentioning

confidence: 99%

Diabetes and Overall Survival among Breast Cancer Patients in the U.S. Military Health System

Shao

Gill

Zahm³

et al. 2018

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background While research suggests that type 2 diabetes mellitus (DM-2) is associated with overall and breast cancer-specific decreased survival, most prior studies of breast cancer survival investigated the effect of pre-existing DM-2 without assessing the effect of DM-2 diagnosed at or after breast cancer diagnosis. This study examined the relationship between DM-2 diagnosed before and after breast cancer diagnosis and overall survival. Methods This study uses linked Department of Defense cancer registry and medical claims data from 9,398 women diagnosed with breast cancer between 1998 and 2007. Cox proportional hazards models were used to assess the association between DM-2 and overall survival. Results Our analyses showed that women with DM-2 diagnosed before breast cancer diagnosis tended to have a higher risk of mortality compared to women without diabetes (HR=1.17, 95% CI=0.95-1.44) after adjustment for potential confounders. Similarly, patients diagnosed with DM-2 at or after breast cancer diagnosis had increased mortality compared with women without DM-2 (HR= 1.39, 95% CI= 1.16-1.66). The similar tendency was also observed among most subgroups when results were stratified by race, menopausal status, obesity, tumor hormone receptor status, and stage. Conclusions Using data from a health system that provides universal healthcare to its beneficiaries, this study showed an increased risk of death associated with DM-2, regardless of whether it was diagnosed before or at/after breast cancer diagnosis. Impact: These results suggest the potential effects of factors independent of the timing of DM-2 clinical diagnosis on the association of DM-2 with overall survival.

show abstract

Section: Introductionmentioning

confidence: 99%

Diabetes and Overall Survival among Breast Cancer Patients in the U.S. Military Health System

Shao

Gill

Zahm³

et al. 2018

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…However, similarly, because of a limited sample to analyze RFS, no sufficient evidence of a significant difference in RFS between patients with and without DM was observed. DM is also independently correlated with poor prognosis in patients with various cancers, such as pancreatic cancer, renal cell carcinoma, and breast cancer . These results suggest that DM is an independent unfavorable prognostic factor for NSCLC after surgical resection.…”

Section: Discussionmentioning

confidence: 67%

“…DM is also independently correlated with poor prognosis in patients with various cancers, such as pancreatic cancer, 31 renal cell carcinoma, 32 and breast cancer. 33 These results suggest that DM is an independent unfavorable prognostic factor for NSCLC after surgical resection. As a result, surgically treated NSCLC patients with DM might benefit from better glucose control and closer postoperative follow-up.…”

Section: Discussionmentioning

confidence: 77%

Diabetes mellitus and survival of non‐small cell lung cancer patients after surgery: A comprehensive systematic review and meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Background Diabetes mellitus (DM) is one of the most common comorbidities in surgically treated non‐small cell lung cancer (NSCLC) patients and has a negative impact on short‐term outcomes. However, the impact of DM on long‐term survival of such patients remains controversial; therefore, we conducted a comprehensive updated meta‐analysis. Methods We systematically searched relevant studies in PubMed, Embase, Cochrane Library, and Web of Science up to 6 September 2018. Hazard ratios (HRs) for the impact of DM on overall survival (OS) and recurrence‐free survival (RFS) of patients with surgically treated NSCLC were extracted and analyzed using the STATA 12.0 package. Results We included 13 cohort studies consisting of 4343 patients (730 patients with DM and 3613 patients without) with surgically treated NSCLC. Meta‐analysis showed that patients with DM had significantly poorer OS (random effects: HR 1.30, 95% confidence interval 1.05–1.60; P = 0.016) than those without. However, with a limited sample size, there was no significant difference in RFS (random effects: HR 1.06, 95% confidence interval 0.71–1.58; P = 0.786) between patients with and without DM after surgical resection of NSCLC. Conclusion DM is an independent unfavorable prognostic factor for patients with surgically treated NSCLC. High‐quality studies with appropriate adjustment for confounding factors are needed to confirm our conclusions.

show abstract

“…Meta-analyses have shown that diabetes mellitus is a risk factor for the development of breast cancer 27 , and that diabetes mellitus is associated with a poorer prognosis in women who develop breast cancer 12,13 . The most recent meta-analysis was published in 2016, including 17 studies and 48,315 women with breast cancer; the results showed that the pooled aHR for poorest overall survival was 1.51, and 1.28 for poorest disease-free survival in patients with diabetes mellitus in comparison with those without diabetes mellitus 13 . In addition, Tsilidis et al 28 carried out an "umbrella review" of meta-analyses of observational studies examining the relationship of diabetes mellitus and cancer, and suggested that only a minority of studies reporting a link between diabetes mellitus and various cancers had "robust" supporting evidence without bias.…”

Section: Discussionmentioning

confidence: 99%

Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer

Wang

Shih

Huang

2019

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction We sought to determine if postmenopausal women who develop breast cancer are at increased risk of developing diabetes mellitus. Materials and Methods The Taiwan National Health Insurance Research Database was searched from 2001 to 2015 for women aged ≥55 years (postmenopausal) with a diagnosis of primary breast cancer. Participants were age‐matched with women without breast cancer in a 1:5 ratio. Cox proportional hazards analyses were used to examine associations between breast cancer, risk factors and the development of diabetes mellitus. Results A total of 4,607 women with primary breast cancer and 23,035 age‐matched controls without breast cancer were included (mean age 58.6 ± 9.1 years). Adjusting for age, income, urbanization, Charlson Comorbidity Index and medical conditions, the risk of diabetes mellitus for participants with breast cancer at 1, 5, 10 and 15 years was 1.70‐, 1.34‐, 1.27‐ and 1.24‐fold higher, respectively, than for participants without breast cancer (adjusted hazard ratio [aHR] 1.70, 95% confidence interval [CI] 1.40–2.05; aHR 1.34, 95% CI 1.17–1.54; aHR 1.27, 95% CI 1.13–1.44; aHR 1.24, 95% CI 1.11–1.40). The risk of diabetes mellitus at 1 year for breast cancer patients receiving hormone therapy was 1.22‐fold higher than in those not receiving hormone therapy (aHR 1.22, 95% CI 0.86–1.74), but without statistical significance. Conclusions Postmenopausal women with breast cancer are at increased risk of developing diabetes mellitus, independent of receiving hormone therapy, and should be closely monitored to establish an early diagnosis and therapeutic intervention for improving related outcomes.

show abstract

Diabetes mellitus and prognosis in women with breast cancer

Cited by 87 publications

References 38 publications

Diabetes and Overall Survival among Breast Cancer Patients in the U.S. Military Health System

Diabetes and Overall Survival among Breast Cancer Patients in the U.S. Military Health System

Diabetes mellitus and survival of non‐small cell lung cancer patients after surgery: A comprehensive systematic review and meta‐analysis

Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer

Contact Info

Product

Resources

About